Indaptus Therapeutics, Inc. Accounts Payable and Other Accrued Liabilities, Current
Indaptus Therapeutics, Inc. (INDP) had Accounts Payable and Other Accrued Liabilities, Current of $615.43 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent · last filed 2026-08-13
- 2026-06-30: Accounts Payable and Other Accrued Liabilities, Current $615.43K.
- 2026-03-31: Accounts Payable and Other Accrued Liabilities, Current $933.00K.
- 2025-12-31: Accounts Payable and Other Accrued Liabilities, Current $6.16M.
- 2025-09-30: Accounts Payable and Other Accrued Liabilities, Current $2.23M.
| Period end | Accounts Payable and Other Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $615.43K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $933.00K 10-Q · filed 2026-05-15 |
| 2025-12-31 | $6.16M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $2.23M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $1.98M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $2.55M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $3.31M 10-K · filed 2026-03-17 |
| 2024-09-30 | $2.13M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.82M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $1.43M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $2.67M 10-K · filed 2025-03-13 |
| 2023-09-30 | $2.26M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $2.00M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $1.72M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $3.35M 10-K · filed 2024-03-13 |
| 2022-09-30 | $2.78M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $3.53M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $3.58M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $4.51M 10-K · filed 2023-03-17 |
| 2021-09-30 | $5.78M 10-Q · filed 2021-11-15 |
| 2020-12-31 | $598.37K 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |